A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This multi-center, double-blind, randomized, placebo-controlled study will evaluate the
change in liver fat content, pharmacokinetics and safety of RO5093151 in patients with
non-alcoholic fatty liver disease. Patients will be randomized to receive either daily oral
doses of RO5093151 or matching placebo. The anticipated time on study treatment is 12 weeks.